Full Description
This five-volume series provides clinicians with a detailed, up-to-date, well-referenced overview of the latest developments in this rapidly expanding feld. It serves as an
authoritative guide to the diagnosis and treatment of platelet disorders.The primary audience for the series is clinicians, residents and fellows in internal medicine,
cardiology and haematology, as well as clinicians (e.g. neurologists, nephrologists, rheumatologists) and basic scientists who may be concerned with disorders and
cellular mechanisms involving platelets.
Contents
Chapter 106: Aspirin.- Chapter 107: P2Y12 inhibitors.- Chapter 108: GPIIb/IIIa antagonists.- Chapter 109: PAR antagonists.- Chapter 110: PDE-adenosine reuptake-inhibitor agents.- Chapter 111: Nitric oxide-releasing or enhancing agents.- Chapter 112: Platelet puringeric receptors as targets for novel anti-inflammatory drugs.- Chapter 113: Novel approaches to antiplatelet therapy.- Chapter 114: Antiplatelet therapy in coronary artery disease.- Chapter 115: Antiplatelet therapy for TIA/stroke.- Chapter 116: Antiplatelet therapy for PAD.- Chapter 117: Laboratory monitoring-guided antiplatelet therapy.- Chapter 118: Antiplatelet therapy for venous thromboembolism.- Chapter 119: Platelets in regenerative medicine.- Chapter 120: Platelet transfusions.- Chapter 121: TPO agonists and agents under development to increase platelet count.- Chapter 122: In vitro generated engineered or enhanced platelets.- Chapter 123: Platelets for gene therapy.- Chapter 124: Platelets as carriers for antitumor therapy.
